Eugia receives FDA approval for Adenosine Injection Single-Dose Vials!
Published: November 03, 2017
On November 02, 2017 Eugia received FDA approval for Adenosine Injection Single-Dose Vials which is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
With an estimated total annual market of $17.3 million through June 2017 according to IMS data, this is an exciting addition to the Eugia portfolio.